Jubilant Pharmova Ltd. makes a corporate announcement

Current weighted average cost of debt: not directly disclosed. The latest reported gross debt is Rs 3,219.5 Crores, with non-current borrowings of Rs 2,971.7 Crores as of Q1 FY27/latest reported balance.^{[1] [2]} FY26 consolidated finance costs were Rs 211.8 Crores.^[3] Dividing this by year-end gross debt gives a 6.58% simple finance-cost proxy, but this is not a true weighted average cost of debt because debt balances, currencies, floating-rate resets and refinancing activity changed during the year.

Specifically disclosed borrowing maturities

The parent-company standalone borrowing table showed only the Rs 50 Crores secured NCD as non-current borrowing at 31 March 2026; the consolidated debt balance is materially larger because it includes group and subsidiary borrowings.^[4]

The USD 225 million term loan that had been repayable in three half-yearly instalments from July 2026 was prepaid through refinancing during FY26; it should therefore not be treated as an existing maturity for the proposed NCD issue.^[5] The replacement financing terms are not specified.

Implication for the Rs 800 Crores issue: the board filing does not identify a particular borrowing or maturity bucket to be refinanced. The proposed NCDs have a tenure of up to five years, with the coupon to be discovered through bidding.^[6] The Rs 2,500 Crores authorization is an aggregate outstanding limit for privately placed non-convertible debt securities over one year, not evidence that Rs 2,500 Crores of incremental debt will necessarily be raised.^[7] Thus, the issue can reasonably provide refinancing flexibility or fund capex, but its precise use and expected reduction in funding cost remain undisclosed.

Verdict: The block deal appears to have changed the institutional holder mix, not the overall institutional ownership in aggregate. The latest category-level snapshot is for June 2026—before the October transaction—and shows FII ownership of 15.87% and DII ownership of 12.40%, or 28.27% institutionally, derived. Promoters held 47.68% and retail/other public shareholders 24.05% ^[8]. A like-for-like comparison with the previous quarter is not possible because the cited shareholding data does not provide the March 2026 category percentages.

Institutional ownership

• In the reported 11-lakh block transaction, Quant Mutual Fund’s holding fell from 1.85% to 1.16%, while Abakkus Four2Eight Opportunities Fund’s holding rose to 1.84% ^[9].
• This is primarily a transfer between institutional investors. Therefore, absent other transactions, the deal should not materially change total institutional ownership; it changes the identity and type of institutional exposure.
• The post-deal position is not yet reflected in the June 2026 quarter-end category split. There is also a data inconsistency: another report says Quant sold a total of 20.81 lakh shares, or 1.30%, while a separate report estimates that Quant could have been left with approximately 0.54%, subject to the assumption that both sales came from its June holding ^{[10] [11]}. The exact current Quant holding therefore requires the next official shareholding filing.

Promoter pledging and encumbrance

Recent promoter filings do indicate a meaningful increase in encumbrance:

• On 17 June 2026, the Hari Shanker Bhartia Family Trust and Shyam Sunder Bhartia Family Trust each created a pledge of 20.50 lakh shares, equivalent to 1.29% of total share capital per trust, in favour of Bajaj Finance.
• Each trust’s post-event encumbered holding was reported at 25.00 lakh shares, or 1.57% of total share capital, versus 4.50 lakh shares, or 0.28%, already encumbered before the creation event ^[12].
• Summed across the two trusts, the new pledges amount to 41.00 lakh shares, or 2.58% of total share capital, while their post-event encumbered holdings total 50.00 lakh shares, or 3.14%, derived from the two trust-level disclosures ^[12].

The filing records pledge creation; it does not establish any release or invocation of these shares. The structured quarterly shareholding feed also does not carry the company’s overall promoter-encumbrance percentage, so the total promoter pledge ratio cannot be compared reliably with the prior quarter.

Relevance to the new debt limit

The pledge is relevant as a promoter-level collateral and financial-risk signal, but it is not, by itself, evidence that Jubilant Pharmova has drawn additional corporate debt or used the new limit. The reported Rs 800-crore initiative is described in news coverage as a fundraising plan, rather than a fully documented debt drawdown ^[11]. At Q1 FY27, reported total debt was Rs 3,219.5 Crores and net debt was Rs 1,952.4 Crores, both unchanged from Q4 FY26 ^{[1] [13]}. Management nevertheless reported net debt/EBITDA rising from 1.5x in March 2026 to 1.8x in June 2026 ^[14], reflecting weaker EBITDA rather than a quarter-on-quarter increase in reported debt.

Verdict: Assuming the proposed Rs 2,500 crore limit refers to net debt, Jubilant Pharmova’s pro-forma net debt-to-EBITDA would be approximately 1.9x. That is roughly 0.95x above its FY24–FY26 average of 0.97x, and materially higher than the FY26 leverage of the closest consolidated API/CDMO references—Alembic at 0.99x, NATCO at 0.29x, and Concord Biotech at -0.03x, where a negative ratio denotes net cash.

Calculation and historical comparison

Jubilant reported Q1 FY27 net debt of Rs 2,338 crore and TTM net debt-to-EBITDA of 1.8x. This implies TTM EBITDA of approximately Rs 1,299 crore; applying the hypothetical Rs 2,500 crore net-debt ceiling gives:

`Pro-forma net debt-to-EBITDA = Rs 2,500 crore / Rs 1,299 crore = approximately 1.92x`

Both inputs are company-reported in the Q1 FY27 leverage table. ^[15]

Thus, the pro-forma ratio would be about 2.0x the recent three-year average. If “three-year average” is instead defined as FY23–FY25, the average is 1.46x, derived from 2.94x, 0.35x and 1.10x ^{[19] [16] [17]}; the pro-forma ratio would still be approximately 0.46x higher.

Peer positioning

Implication: At approximately 1.9x, Jubilant would remain below a highly levered balance sheet in absolute terms, but it would be clearly more leveraged than most Indian API/CDMO comparators. The gap is partly explained by Jubilant’s ongoing investment in PET radiopharmacy and CDMO capacity; management has said net debt-to-EBITDA should remain range-bound and expects margin improvement from H2 FY27 as SPECT production normalises. ^[14]

Key caveat: If Rs 2,500 crore is a gross-debt ceiling rather than a net-debt ceiling, the ratio cannot be calculated directly. Jubilant’s Q1 FY27 total debt was Rs 3,219.5 crore ^[1], while the company-reported net debt was Rs 2,338 crore ^[15]; the resulting net debt would depend on the cash balance and debt repayment required. Also, the KPI-reported Q1 ratio of 7.29x ^[30] uses a single-quarter EBITDA denominator and should not be compared with the company’s 1.8x TTM figure.

_Scope note: this comparison also included AstraZenca Pharma India Ltd. (ASTRAZEN), which the answer above does not cover. Ask about any of them for a full side-by-side._